BPC-157, KPV, TB-500, MOTS-C, Epitalon and Semax moved closer to possible compounded use, while the panel rejected Emideltide.
News Content
The US Food and Drug Administration’s Pharmacy Compounding Advisory Committee has recommended adding six of seven unapproved peptides to the Section 503A Bulk Drug Substances List, potentially creating a legal pathway for eligible pharmacies to prepare them for individual patients with prescriptions.
During the two-day meeting, the panel supported BPC-157, KPV, TB-500, MOTS-C, Epitalon and Semax. It rejected Emideltide, also known as delta sleep-inducing peptide. The recommendations are non-binding, and the FDA has not yet issued a final decision.
Advertisement
Six Peptides Clear a Closely Watched Regulatory Hurdle
The committee reviewed each substance for specific nominated uses:
- BPC-157: Ulcerative colitis
- KPV: Wound healing and inflammatory conditions
- TB-500: Wound healing
- MOTS-C: Obesity and osteoporosis
- Epitalon: Insomnia
- Semax: Cerebral ischaemia, migraine and trigeminal neuralgia
These are proposed uses considered during the meeting—not FDA-approved indications. The substances are also not components of approved drug products reviewed for these conditions.
The committee endorsed BPC-157, KPV, TB-500 and MOTS-C during the first day. On the second day, Epitalon was supported by a 7–5 vote with one abstention, while Semax received eight votes in favour, five against and one abstention.
Supporters argued that allowing licensed compounding pharmacies to prepare these substances could offer greater medical supervision and reduce consumer reliance on unregulated online products sold as “research chemicals.” Critics countered that legal access should follow stronger evidence of safety and clinical benefit.
Advertisement
Why Emideltide Was the Only Peptide Rejected
The committee rejected Emideltide in a narrow 6–7 vote with one abstention. It had been proposed for conditions including insomnia, narcolepsy and opioid withdrawal.
FDA reviewers said the available evidence was insufficient. The reported research included a single case involving narcolepsy and two small, uncontrolled opioid-withdrawal studies. Questions were also raised because some studies used intravenous administration, while the proposed compounded product would be injected under the skin.(1✔ ✔Trusted Source
FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next?
The agency also noted that approved and better-studied treatments already exist for the proposed conditions. FDA official Katie Park said there was a lack of safety and effectiveness data supporting Emideltide for these uses.
Advertisement
Limited Research Keeps Peptide Safety Under Scrutiny
FDA staff had recommended against placing all seven peptides on the compounding list. Their concerns included limited human studies, uncertain product characterization, inconsistent formulations, peptide-related impurities and the possibility of harmful immune reactions.
For some substances, the agency found little or no human exposure information through the proposed route of administration. Regulators also questioned whether differently prepared products described under the same peptide name would contain chemically equivalent substances.
During the hearing, FDA regulatory official Russell Wesdyk questioned how a poorly defined substance could be safely added to the list:
“If you don’t know what it is and I don’t know what it is, how do I put it on the list?”
Panel supporters viewed compounding as a harm-reduction approach, while public-health advocates warned that market demand should not substitute for controlled trials and rigorous regulatory review. Several reports also raised concerns about panel members with professional links to peptide clinics and businesses.
Compounding Access Would Not Mean FDA Approval
Placement on the 503A Bulks List would not make the peptides FDA-approved medicines or products that consumers could purchase freely from store shelves.
It could allow certain state-licensed pharmacies or physicians to use the bulk substances to prepare customized medicines for individually identified patients when federal compounding requirements are satisfied.
However, compounded products do not undergo the same premarket review for safety, effectiveness, dosage, manufacturing quality and labelling as FDA-approved drugs. Poor compounding practices may result in contamination, incorrect strength or unexpected ingredients.(1✔ ✔Trusted Source
FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next?
Patients should therefore not interpret the committee vote as confirmation that the six peptides are proven treatments. Products bought from overseas or unverified online sellers may carry additional risks because their identity, purity and dosage may be unknown.
What Happens Before Access Can Change?
The FDA must review the committee votes, meeting records, scientific evidence and public comments before deciding whether to accept or reject the recommendations.
A formal change may involve proposed regulatory action, public feedback and a final agency decision. The process could take several months or longer, and the FDA is not required to follow its advisory committee’s recommendations.
Health Secretary Robert F. Kennedy Jr. has publicly supported wider access to peptide treatments, but FDA scientists and safety advocates continue to call for stronger clinical research, clearer product standards and reliable monitoring of adverse effects.
Until the FDA announces a final decision, the six peptides remain unapproved for the evaluated uses. Patients considering peptide products should consult a qualified healthcare professional and avoid relying solely on social-media testimonials or products labelled only for research purposes.
Reference:
- FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next?- (https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915)
Source-Medindia